BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 27665858)

  • 1. Sirolimus-eluting stent is superior to paclitaxel-eluting stent for coronary intervention in patients with renal insufficiency: Long-term clinical outcomes.
    Ann SH; Seo SM; Kim PJ; Koh YS; Her SH; Shin DI; Park HJ; Park CS; Lee JM; Kim DB; Chang K; Chung WS; Seung KB
    Cardiol J; 2016; 23(6):637-646. PubMed ID: 27665858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of renal insufficiency on safety and efficacy of drug-eluting stents compared to bare-metal stents at 6 years.
    Simsek C; Magro M; Boersma E; Onuma Y; Nauta S; Valstar G; van Geuns RJ; van der Giessen W; van Domburg R; Serruys P;
    Catheter Cardiovasc Interv; 2012 Jul; 80(1):18-26. PubMed ID: 21735520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sirolimus- versus paclitaxel-eluting stents for the treatment of coronary bifurcations results: from the COBIS (Coronary Bifurcation Stenting) Registry.
    Song YB; Hahn JY; Choi SH; Choi JH; Lee SH; Jeong MH; Kim HS; Seong IW; Yang JY; Rha SW; Jang Y; Yoon JH; Tahk SJ; Seung KB; Park SJ; Gwon HC
    J Am Coll Cardiol; 2010 Apr; 55(16):1743-50. PubMed ID: 20394879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Four-year clinical outcome of sirolimus- and paclitaxel-eluting stents compared to bare-metal stents for the percutaneous treatment of stable coronary artery disease.
    Simsek C; Onuma Y; Magro M; de Boer S; Battes L; van Domburg RT; Boersma E; Serruys PW;
    Catheter Cardiovasc Interv; 2010 Jul; 76(1):41-9. PubMed ID: 20310019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcome of the unrestricted use of everolimus-eluting stents compared to sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients: the Bern-Rotterdam diabetes cohort study.
    Simsek C; Räber L; Magro M; Boersma E; Onuma Y; Stefanini GG; Zanchin T; Kalesan B; Wenaweser P; Jüni P; van Geuns RJ; van Domburg RT; Windecker S; Serruys PW
    Int J Cardiol; 2013 Dec; 170(1):36-42. PubMed ID: 24196314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
    Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Six-year clinical outcomes of first-generation drug-eluting stents: a propensity-matched analysis.
    Tarantini G; Barioli A; Facchin M; Frigo AC; Napodano M; Buja P; D'Amico G; Iliceto S; Isabella G
    Coron Artery Dis; 2013 Aug; 24(5):440-8. PubMed ID: 23695366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: four year results of the PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary angiOplasty (PASEO) randomized trial.
    Di Lorenzo E; Sauro R; Varricchio A; Capasso M; Lanzillo T; Manganelli F; Mariello C; Siano F; Pagliuca MR; Stanco G; Rosato G; De Luca G
    Am Heart J; 2009 Oct; 158(4):e43-50. PubMed ID: 19781402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential long-term outcomes of zotarolimus-eluting stents compared with sirolimus-eluting and paclitaxel-eluting stents in diabetic and nondiabetic patients: two-year subgroup analysis of the ZEST randomized trial.
    Jang SJ; Park DW; Kim WJ; Kim YH; Yun SC; Kang SJ; Lee SW; Lee CW; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2013 Jun; 81(7):1106-14. PubMed ID: 22899589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of outcomes after percutaneous coronary intervention for chronic total occlusion using everolimus- versus sirolimus- versus paclitaxel-eluting stents (from the Korean National Registry of Chronic Total Occlusion Intervention).
    Lee MH; Lee JM; Kang SH; Yoon CH; Jang Y; Yu CW; Park HS; Lee SH; Hur SH; Kim MH; Rha SW; Gwon HC; Chae IH; Kim HS
    Am J Cardiol; 2015 Jul; 116(2):195-203. PubMed ID: 26001819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of 5-year clinical outcomes between sirolimus-versus paclitaxel-eluting stent: Korean multicenter network analysis of 9000-patient cohort.
    Park K; Park KW; Rha SW; Bae JH; Hur SH; Park JS; Yoon JH; Jang Y; Jeong MH; Kim HS
    Circ Cardiovasc Interv; 2012 Apr; 5(2):174-84. PubMed ID: 22396583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison between sirolimus- and paclitaxel-eluting stents for the treatment of older patients affected by coronary artery disease: results from a single-center allcomers registry.
    Buja P; Lanzellotti D; Isabella G; Napodano M; Panfili M; Favaretto E; Iliceto S; Tarantini G
    Heart Vessels; 2012 Nov; 27(6):553-8. PubMed ID: 21989862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy outcomes of overlapping second-generation everolimus-eluting stents versus first-generation drug-eluting stents.
    Kitabata H; Loh JP; Pendyala LK; Badr S; Dvir D; Barbash IM; Minha S; Torguson R; Chen F; Satler LF; Suddath WO; Kent KM; Pichard AD; Waksman R
    Am J Cardiol; 2013 Oct; 112(8):1093-8. PubMed ID: 23827397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long time clinical outcomes of limus-eluting stent versus paclitaxel-eluting stent in patients undergoing percutaneous coronary artery intervention: A meta-analysis of randomized controlled clinical trials.
    Gao L; Hu X; Hou Y; Xue Q
    Cardiol J; 2014; 21(3):211-9. PubMed ID: 24526500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of drug-eluting versus bare-metal stent implantation in ST-elevation myocardial infarction patients with renal insufficiency: results from the national registry in Korea.
    Kim KH; Koo BK; Min HS; Park SK; Kim CH; Park KW; Park BJ; Jeong MH; Cho MC; Lee SR; Chae SC; Seong IW; Choi DJ; Kim HS
    Int J Cardiol; 2012 Jan; 154(1):71-7. PubMed ID: 20888053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term clinical outcomes after percutaneous coronary intervention for ostial/mid-shaft lesions versus distal bifurcation lesions in unprotected left main coronary artery: the DELTA Registry (drug-eluting stent for left main coronary artery disease): a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment.
    Naganuma T; Chieffo A; Meliga E; Capodanno D; Park SJ; Onuma Y; Valgimigli M; Jegere S; Makkar RR; Palacios IF; Costopoulos C; Kim YH; Buszman PP; Chakravarty T; Sheiban I; Mehran R; Naber C; Margey R; Agnihotri A; Marra S; Capranzano P; Leon MB; Moses JW; Fajadet J; Lefevre T; Morice MC; Erglis A; Tamburino C; Alfieri O; Serruys PW; Colombo A
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1242-9. PubMed ID: 24355114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
    Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three-year patient-related and stent-related outcomes of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice (from the Multicenter Prospective EXCELLENT and RESOLUTE-Korea Registries).
    Lee JM; Park KW; Han JK; Yang HM; Kang HJ; Koo BK; Bae JW; Woo SI; Park JS; Jin DK; Jeon DW; Oh SK; Park JS; Kim DI; Hyon MS; Jeon HK; Lim DS; Kim MG; Rha SW; Her SH; Hwang JY; Kim S; Choi YJ; Kang JH; Moon KW; Jang Y; Kim HS
    Am J Cardiol; 2014 Nov; 114(9):1329-38. PubMed ID: 25217457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus-eluting stents versus sirolimus- or paclitaxel-eluting stents: two-year results from the Guthrie Health Off-Label Stent (GHOST) registry.
    Harjai KJ; Kondareddy S; Pinkosky B; Harjai N; Orshaw P; Boura J
    J Interv Cardiol; 2013 Apr; 26(2):153-62. PubMed ID: 23363439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.